Work Area: Trade secrets

Latest content

China bill moving through US Senate would create list of ‘IP violators’

The Strategic Competition Act of 2021 could also see increased use of sanctions to combat IP theft

28 April 2021

TRIPS covid vaccine IP waiver proposal fails to address crucial questions

President Biden and other leaders are coming under pressure to agree a suspension of IP rights, but a key point has been missed

20 April 2021

How India can chart a course to IP leadership

Top voices from industry and private practice reckon with the strengths and weaknesses of country’s IP environment

15 April 2021

How mapping IP and other intangibles can drive business value

The long read: Charting the value of intellectual assets can be difficult, writes Deloitte's Tim Heberden, but there are ways of showing their role as the drivers of revenue, efficiency and risk, and even in locating the value flows between them

14 April 2021

Top bitcoin hardware firms to clash in Chinese IP suit

Bitmain’s trade secrets complaint against MicroBT in Beijing follows failed patent assertion attempt

13 April 2021

Six takeaways from the $1.8 billion finale to the LG Energy Solutions - SK Innovation IP dispute

As political wrangling and potential for commercial fallout mounted, the two Korean battery suppliers reached an eleventh-hour settlement deal yesterday

12 April 2021

Legislators tell the White House that IP must move up the to-do list

After letter from Senators Leahy and Tillis telling President Biden to pick up the pace of appointments, Hill source tells IAM that IP needs to be seen as a tier one priority

31 March 2021

Latest Humira dispute highlights biosimilar trade secrets dangers

As the biologics industry expands, strategies for protecting proprietary and confidential information are becoming ever-more essential

30 March 2021

Taiwan’s Largan walks away from IP fight with record damage award, CEO apology and big ownership stake in rival

Recent PTAB filings, however, suggest that the lens maker’s conflict with US tech company HP continues

11 March 2021

Creative monetisation of de-prioritised IP is the next frontier for Big Pharma strategists

Despite their commitments to specialisation, large life sciences companies must not neglect the value of sidelined patents, know-how and other intangible assets

06 March 2021

Get unlimited access to all IAM content